Eggs for Cash: Pitting Choice Against Risk
By Diane Tober and Francine Coeytaux,
RH Reality Check
| 09. 04. 2013
On August 13, California Gov. Jerry Brown vetoed AB 926, a bill sponsored by the American Society for Reproductive Medicine (ASRM) that would have permitted researchers to pay women for their eggs at the same rate as the fertility industry (approximately $5,000 to $10,000 per cycle). This bill would have overturned protections implemented by the almost unanimous 2006 passage of SB 1260. Authored by Sen. Deborah Ortiz (D-Marina del Rey), a longtime reproductive rights advocate, SB 1260 included a ban on paying women to provide eggs for research in order to protect against “undue inducement.” In his veto message, Gov. Brown wrote, “In medical procedures of this kind, genuinely informed consent is difficult because the long-term risks are not adequately known. Putting thousands of dollars on the table only compounds the problem.”
The debate in California around this recent bill illustrates the tensions throughout the reproductive rights and justice movements about what it means to be pro-woman. Where are the boundaries between autonomy and health and safety? Does autonomy mean that we cannot seek reasonable health and safety regulations...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
CGS is excited to announce the launch of a new anti-eugenics initiative that has been years in the making. Legacies of Eugenics in Science, Medicine, and Technology kicks off with a monthly essay series published at the Los Angeles Review of Books that will expose and contest the reemergence of eugenic ideas in contemporary health sciences, human biotechnology, public health, and medicine. Community and campus-based events featuring the authors are also being planned. The project is a collaboration among CGS...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...